FibroGen Inc $ 41.77 -0.05 (-0.12%)
Volume:
241,638
Avg Vol (1m):
761,167
Market Cap $:
3.72 Bil
Enterprise Value $:
3.25 Bil
P/E (TTM):
0.00
P/B:
8.10
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 11.41 | ||
| Equity-to-Asset | 0.56 | ||
| Debt-to-Equity | 0.1 | ||
| Debt-to-EBITDA | -0.55 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 5.83 | ||
| Beneish M-Score | 3.76 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -47.27 | ||
| Net Margin % | -42.75 | ||
| ROE % | -20.45 | ||
| ROA % | -12.77 | ||
| ROC (Joel Greenblatt) % | -66.09 | ||
| 3-Year Revenue Growth Rate | 0.5 | ||
| 3-Year EBITDA Growth Rate | 2.9 | ||
| 3-Year EPS without NRI Growth Rate | 1.5 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 8.1 | ||
| PS Ratio | 14.72 | ||
| EV-to-EBIT | -30.4 | ||
| EV-to-EBITDA | -38.08 | ||
| EV-to-Revenue | 12.65 | ||
| Current Ratio | 11.14 | ||
| Quick Ratio | 11.01 | ||
| Days Inventory | 764.97 | ||
| Days Sales Outstanding | 83.1 | ||
| Days Payable | 493.97 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.2 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 8.1 | ||
| Earnings Yield (Greenblatt) % | -3.29 |